Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances

Introduction: Acute lymphoblastic leukemia (ALL) is the first neoplasm where the assessment of early response to therapy by minimal residual disease (MRD) monitoring has proven to be a fundamental tool to guide therapeutic choices. The most standardized methods to study MRD in ALL are multi-parametr...

Full description

Bibliographic Details
Main Authors: Irene Della Starza, Sabina Chiaretti, Maria S. De Propris, Loredana Elia, Marzia Cavalli, Lucia A. De Novi, Roberta Soscia, Monica Messina, Antonella Vitale, Anna Guarini, Robin Foà
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-08-01
Series:Frontiers in Oncology
Subjects:
acute lymphoblastic leukemia (ALL)
minimal residual disease (MRD)
flow cytometry
real time quantitative PCR (RQ-PCR)
next generation flow cytometry (NGF)
digital droplet PCR (ddPCR)
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00726/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00726/full

Similar Items